GlassScriptPhysician profile
Melissa E Manhart
NPI 1679786990
$4,316.43
in general payments reported to CMS, 2019-2025
35 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,281 · 2022: $807 · 2023: $967 · 2024: $1,034 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,228.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.11 | 2021-2025 | Jardiance, Synjardy, Combivent Respimat |
| Lilly USA, LLC | $417.44 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $364.66 | 2021-2025 | |
| Novo Nordisk INC | $265.25 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $263.38 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $230.43 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $196.92 | 2023-2025 | Rexulti |
| Abbott Laboratories | $158.14 | 2023-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $153.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $152.52 | 2021-2022 | |
| Glaxosmithkline, LLC. | $142.10 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $139.89 | 2021-2024 | Austedo Xr |
| Merck Sharp & Dohme LLC | $123.70 | 2021 | |
| Amgen INC. | $123.19 | 2021-2024 | Prolia, Evenity, Otezla |
| Sumitomo Pharma America, INC. | $108.47 | 2023-2024 | Gemtesa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $101.24 | 2021-2024 | Breztri, Farxiga |
| Pfizer INC. | $100.17 | 2022-2024 | |
| Amarin Pharma, INC. | $93.22 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.57 | 2021-2022 | |
| Astellas Pharma US INC | $82.07 | 2021-2023 | Veozah |
| Averitas Pharma INC. | $71.11 | 2024 | Qutenza |
| Esperion Therapeutics, INC. | $67.75 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.80 | 2022 | |
| Idorsia Pharmaceuticals US INC | $54.65 | 2022-2024 | Quviviq |
| Eisai INC. | $46.77 | 2021 | |
| Lundbeck LLC | $41.86 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $33.84 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $31.56 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.99 | 2022 | |
| Nevro Corp. | $17.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.66 | 2021 | |
| Cranial Technologies, INC | $14.83 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.32 | 2022 | |
| Edwards Lifesciences Corporation | $13.28 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Dynavax Technologies Corporation | $12.89 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Manhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.